Skip to main content

Most Popular

covid coronavirus virus

New Onset Rheumatic Disorders with COVID-19 Infection

Jan 05, 2022

The journal Cells has published a review of new rheumatic disorders following COVID-19 infection. Rheumatologists have infrequently noted such events and wondered what is the true incidence or range of possible manifestations.

Read Article

Best of 2021: EULAR Guidelines on Intraarticular Therapy

Dec 20, 2021

EULAR has published evidence-based recommendations on the use of intra-articular therapies (IAT) based on the literature review and recommendations of a multidisciplinary international task force. These IAT recommendations apply to adult patients with peripheral arthropathies.

Read Article

Best of 2021: 11 Drugs That Cause Arthritis

Dec 27, 2021

This is the #1 question I get from new consults: “How did I get arthritis?”

But as the aching are asking, they are really thinking these joint complaints must be due to:

Read Article

2021 Rheumatology Year in Review

Jan 08, 2022

“One faces the future with one’s past” – Pearl S. Buck

2021 was the year we waited for the other shoe to drop; with the pandemic stone in your shoe, you waited for:

Read Article

Autoantibody Associations in Systemic Sclerosis

Jan 04, 2022

Analysis of two large cohorts of systemic sclerosis (SSc) patients shows a signfiicant minority of patients to have autoantibodies typical of rheumatoid erosive arthrits, but their presence in SSc patients was associated with unique manifestations of SSc. 

Read Article

Best of 2021: Potential Birth Defects with Hydroxychloroquine

Dec 23, 2021

Hydroxychloroquine (HCQ) is one of the safest meds used in rheumatology, but there is new claims data suggesting a small increase in the risk of malformations associated with first-trimester HCQ use.

Read Article

Hold Myophenolate or Not with COVID-19 Vaccination?

Jan 13, 2022

While the American College of Rheumatology (ACR) recommends holding mycophenolate (MMF) in rheumatic and musculoskeletal diseases (RMD) patients receiving COVID-19 vaccines, there is limited data on such an approach.

Read Article

Biologic Treatment of Primary Sjogrens with Ianalumab

Jan 11, 2022

Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24.

Read Article

BEAT LUPUS - Belimumab after Rituximab in SLE

Jan 11, 2022

A recent trial published in Annals of Internal Medicine analyzed the effects of B-cell depletion (rituximab) followed by B-cell suppression (belimumab) and showed effective lowering of anti-dsDNA titers and and fewer severe flare in patients with systemic lupus erythematosus (SLE).

Read Article

Best of 2021: FDA Puts Boxed Warnings on JAK Inhibitors

Dec 30, 2021

Based on the safety review of tofacitinib in Pfizer's Oral Surveillance (1133) study, the FDA has added serious boxed warnings to all three marketed JAK inhibitors (for inflammatory diseases) and formalized the recommendation that patients should be started on a TNF inhibitor (TNFi) before trying

Read Article
burnout work overworked

Best of 2021: Rheumatologists Rank 2nd in Physician Burnout

Dec 22, 2021

The 2021 Medscape Survey on Physician burnout ranks rheumatology second, just behind Critical Care medicine.

Read Article
Psoriasis, arms, PsA

KEEPSaKe-1 Trial in Psoriatic Arthritis - IL-23 Inhibition is Effective

Jan 12, 2022

The results of the KEEPSaKE-1 study in psoriatic arthritis (PsA) has been published and shows that risankizumab (RIZ), an IL-23 inhibitor, showed significant clinical improvements when given to active PsA patients who failed or were intolerant to ≥1 csDMARD.

Read Article
COVID vaccine vials

Best of 2021: Israel provides COVID vaccine answers for rheumatic disease patients

Dec 28, 2021

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a br

Read Article
RheumNow Podcast square

Best of 2021: Jack of All Subspecialties

Dec 31, 2021

Dr. Jack Cush reviews the news and journal articles from the past week on

Read Article
Lungs ILD

Best of 2021: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

Dec 21, 2021

Genentech announced March 4th that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adults SSc-ILD.

Read Article
covid vaccine needle vaccination

Safety of COVID-19 Vaccines in Rheumatic Patients

Jan 03, 2022

Since the introduction of COVID-19 vaccines in January 2021, rheumatologists have fully advocated the protective benefits of their use - yet many have rarely noted flares and reactive side effects worrisome to patients.  Now a multinational study shows that the use of COVID vaccination in rheumat

Read Article

Best of 2021: Steroid Poker

Dec 29, 2021

It began as many cases do: an ill patient, in the ICU, with signs and symptoms across several body systems, yet no clear unifying diagnosis on admission. With things stabilizing, the internal medicine hospital team on which I was serving as hospitalist that week, assumed care of the patient.

Read Article
pill pillbox adherence

Comorbidities Drive Risk of Severe Outcomes with COVID-19

Jan 06, 2022

The current edition of the MMWR from the CDC shows that among those vaccinated against COVID-19, there is a low risk of severe outcomes (hospitalization and death); the highest risk is seen in those with multiple comorbidities.

Read Article

Clinical Practice Guidelines for Multisystem Inflammatory Syndrome in Children

Jan 05, 2022

Multisystem inflammatory syndrome in children (MIS-C) is new and serious complication of COVID-19 that preferentially affects adolescents. A review of proposed management guidelines is compiled in this report, suggesting a unified approach to therapeutic management of MIS-C.

Read Article